TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Telix Pharmaceuticals Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026
$10.74+0.05 (+0.47%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.06 (−0.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Telix Pharmaceuticals Ltd grew revenue 55.6% to $803.79M over fiscal 2025. Operating income fell 46.0% to $29.78M, moving the operating margin from 10.7% to 3.7%. Free cash flow was -$42.99M, down 334.0% from a year earlier.
Revenue
$803.79M
+55.6% vs. a year earlier
Operating income
$29.78M
-46.0% vs. a year earlier
Free cash flow
-$42.99M
-334.0% vs. a year earlier
EPS, diluted
-$0.02
-121.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $803.79M
- Net income
- -$7.13M
- EPS, diluted
- -$0.02
- Free cash flow
- -$42.99M
Four years at a glance
Fiscal years 2022 to 2025, USD
Revenue
$803.79M+55.6% YoY
Gross profit
$426.44M+26.9% YoY
Operating income
$29.78M-46.0% YoY
Net income
-$7.13M-121.2% YoY
EPS, diluted
-$0.02-121.6% YoY
Free cash flow
-$42.99M-334.0% YoY
Reported period